Quantcast

Latest Boehringer Ingelheim Stories

2014-07-23 16:26:55

British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients and prompt them to stop taking PRADAXA, thereby increasing their risk of stroke. To be clear, many of the allegations made...

2014-07-16 12:28:07

For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). The efficacy and safety of nintedanib in the treatment of IPF has not been established. "Boehringer Ingelheim is proud that...

2014-07-15 23:11:27

Dr. Erik R. Martinez appointed to lead LLOYD, Inc. Shenandoah, Iowa (PRWEB) July 15, 2014 LLOYD, Inc. has announced the appointment of Dr. Erik R. Martinez as CEO. Dr. Martinez assumed responsibilities on 7/7/2014 and will succeed interim CEO Dr. W. Eugene Lloyd, who will continue as Chairman of the Board of Directors of LLOYD, Inc. Dr. Lloyd states: “The Board or Directors of LLOYD, Inc. and all employees are delighted that Dr. Martinez has joined the company in this very important...

2014-07-15 12:29:41

WASHINGTON and RIDGEFIELD, Conn., July 15, 2014 /PRNewswire-USNewswire/ -- NCLR (National Council of La Raza) today released a report on Latino health, "An Inside Look at Chronic Disease and Health Care among Hispanics in the United States." The study found that even though Latinos are accessing health care, they face barriers to maintaining their health including affordability, immigration status and language. Of those surveyed, 25 percent had visited an emergency room in the past year, a...

2014-07-08 08:30:12

- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today in the American Society of Hematology journal Blood. Volasertib has not been approved by the...

2014-07-02 08:27:39

RIDGEFIELD, Conn., July 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing by the U.S. Food & Drug Administration (FDA) and granted Priority Review designation. The application for nintedanib is currently under review for the treatment of people with idiopathic pulmonary fibrosis (IPF), a rare, progressive and fatal lung disease that affects...

2014-06-27 08:25:26

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company and Boehringer Ingelheim is the first biosimilar insulin...

2014-06-27 08:25:19

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim is the first...

2014-06-26 08:28:27

Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to idarucizumab*, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa (dabigatran etexilate mesylate). "Boehringer Ingelheim is pleased that the...

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access program (EAP) for its investigational compound nintedanib, for people diagnosed with idiopathic pulmonary fibrosis (IPF) and who meet certain eligibility criteria. Nintedanib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA). The safety and efficacy of...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related